LCD Reference Article Response To Comments Article

Response to Comments: Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms- Related to Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms (L37810)

A56216

Expand All | Collapse All
Draft Article
Draft Articles are works in progress and not necessarily a reflection of the current billing and coding practices. Revisions to codes are carefully and thoroughly reviewed and are not intended to change the original intent of the LCD.

Document Note

Note History

Contractor Information

Article Information

General Information

Source Article ID
N/A
Article ID
A56216
Original ICD-9 Article ID
Not Applicable
Article Title
Response to Comments: Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms- Related to Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms (L37810)
Article Type
Response to Comments
Original Effective Date
04/01/2019
Revision Effective Date
N/A
Revision Ending Date
N/A
Retirement Date
N/A

CPT codes, descriptions, and other data only are copyright 2023 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2023 American Dental Association. All rights reserved.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

CMS National Coverage Policy

N/A

Article Guidance

Article Text

As an important part of Medicare Local Coverage Determination (LCD) development, National Government Services solicits comments from the provider community and from members of the public who may be affected by or interested in our LCDs. The purpose of the advice and comment process is to gain the expertise and experience of those commenting.

We would like to thank those who suggested changes to the Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms LCD. The official notice period for the final LCD begins on February 14, 2019 and the final determination will become effective on April 1, 2019.

Response To Comments

Number Comment Response
1

A joint comment from the Association for Molecular Pathology (AMP) and the College of American Pathologists (CAP) noted: “We agree with the summary of evidence as articulated, but would request National Government Services (NGS) consider making the following changes to reflect recently published evidence.”

“We suggest modifying the final sentence in paragraph two of Mismatch Repair Deficiency (dMMR) to read: “In sporadic tumors, epigenetic changes (e.g. acquired hypermethylation of the promoters of both alleles of MLH1 gene), rather than gene mutations, usually account for defective MMR gene expression”. A fraction of MSI-positive tumors which lack promoter methylation or germline mutations carry somatic mutations in MLH1 and MLH2 (Herfarth KK et al. 1997, Mensenkamp AR et al. 2014).”

NGS Agrees.

2

“Several additional studies have been published showing mismatch repair-deficient colorectal cancers respond to PD-1 therapy and provide further evidence for a relationship between MSI status and therapeutic response. We recommend adding the references from Overman M et al, 2017 and Le DT et al, 2017 to the final sentence in paragraph two of Mismatch Repair Deficiency (dMMR) subsection.”

NGS agrees but believes paragraph three (rather than two) was meant.

3

“AMP and CAP applaud NGS for proposing coverage for genomic sequential analysis panels for mCRC. We respectfully request that NGS consider removing clause 3 under the Indications and Limitations of Coverage Section of the dLCD, which requires that the patient “has not had prior RAS/BRAF testing.” Colon cancers evolve over time and a tumor that once tested to be RAS wild-type can develop RAS (or other) mutation as a mechanism of resistance over time. This mutation would make the patient resistant to epidural growth factor receptor (EGFR) targeted therapies (Misale et al, 2012). In one study, the KRAS mutations consistently occurred between 5 and 6 months post treatment (Diaz et al, 2012). Salient examples of acquired alterations associated with secondary resistance to EGFR targeted therapies include KRAS mutation, NRAS mutation, BRAF mutation, KRAS amplification, HER2 amplification and MET amplification (Leto, Trusolino, 2014). Therefore, re-testing in a patient that was previously tested and determined to be RAS wild-type will allow the ability to detect a resistance mutation and potentially discontinue the use of expensive EGFR targeted therapies in patients with advanced colorectal cancer.”

NGS agrees with the potential need for re-testing after initiation of anti-EGFR therapy if resistance develops. The exclusion of patients with prior RAS/BRAF testing targeted newly diagnosed mCRC, before initiation of anti-EGFR therapy, given the good concordance between the primary and synchronous metastasis. The draft clause will be qualified to allow for re-testing “after initiation of anti-EGFR therapy with evidence of acquired resistance.” Early and definitive identification of a resistance mutation will expedite discontinuation of EGFR targeted therapy.

4

The joint AMP/CAP comment also requested the addition of a number of malignancy related ICD-10 code additions (primary, secondary, and personal history of).

NGS agrees with the addition of malignant carcinoid tumor codes (C7A.02-C7A.026). The other primary tumor codes were either not colorectal specific or were too site nonspecific. NGS has opted not to include secondary malignancy diagnoses on the policy. Finally, since the “personal history of” Z codes “identifies a malignancy that has been previously treated or removed but for which there is no current treatment for the condition and no evidence of the disease,” those codes would not apply and will not be included.

 

5

AMP/CAP also requested a similar addition of codes to the NSCLC portion of the policy.

Only the mCRC section of the draft was open to comment but AMP/CAP is welcome to submit a reconsideration request after the draft becomes effective.

6

A comment from UMASS Memorial Health Care also requested the addition of secondary malignancy codes (C78.0 – C78.89, C79.0-C79.9).

NGS disagrees. See response 5.

7

An additional comment from UMASS Memorial Health Care requested the addition of “consideration of coverage of genomic sequence analysis panels in the treatment of ovarian cancer.”

Only the mCRC section of the draft was open to comment but UMASS is welcome to submit a reconsideration request after the draft becomes effective.

N/A

Coding Information

Bill Type Codes

Code Description

Please accept the License to see the codes.

N/A

Revenue Codes

Code Description

Please accept the License to see the codes.

N/A

CPT/HCPCS Codes

Please accept the License to see the codes.

N/A

CPT/HCPCS Modifiers

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-CM Codes that Support Medical Necessity

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-PCS Codes

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

Additional ICD-10 Information

Bill Type Codes

Code Description

Please accept the License to see the codes.

N/A

Revenue Codes

Code Description

Please accept the License to see the codes.

N/A

Other Coding Information

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format
Code Descriptor Generic Name Descriptor Brand Name Exclusion Effective Date Exclusion End Date Reason for Exclusion
N/A N/A
N/A
Non-Excluded CPT/HCPCS Ended Codes - Table Format
Code Descriptor Generic Name Descriptor Brand Name Exclusion Effective Date Exclusion End Date Reason for Exclusion
N/A

Revision History Information

Revision History Date Revision History Number Revision History Explanation
N/A

Associated Documents

Medicare BPM Ch 15.50.2 SAD Determinations
Medicare BPM Ch 15.50.2
Related Local Coverage Documents
N/A
Related National Coverage Documents
N/A
SAD Process URL 1
N/A
SAD Process URL 2
N/A
Statutory Requirements URLs
N/A
Rules and Regulations URLs
N/A
CMS Manual Explanations URLs
N/A
Other URLs
N/A
Public Versions
Updated On Effective Dates Status
02/07/2019 04/01/2019 - N/A Currently in Effect You are here

Keywords

N/A